Endotoxin Testing by Gel-Clot Assay
Uses LAL gel formation for a limit test or dilution-endpoint estimate. A practical starting point for defined-threshold assessments when the sample supports a clear, valid reaction.
Find a testing approach that matches your sample and the question you need to answer. Creative BioMart provides endotoxin testing services and project discussions covering LAL methods, recombinant Factor C and selective solid-phase approaches, alongside broader pyrogen testing routes. Explore the methods below, compare their outputs and share your requirements for a sample-specific project review.
Bacterial endotoxin testing assesses endotoxin associated with Gram-negative bacteria. Pyrogen testing addresses a broader biological question: whether a material can produce a pyrogenic response in the selected test system. A method that measures endotoxin does not, by itself, establish the absence of non-endotoxin pyrogens.
Method selection therefore starts with the intended use, sample matrix and required result. A threshold-based decision, a quantitative endotoxin measurement and a broader pyrogen assessment are different objectives. The applicable specification, dilution constraints and product-specific suitability work help determine which approach can support the project.
Choose a service below for more detailed information about the assay principle, sample considerations and project scope.
Uses LAL gel formation for a limit test or dilution-endpoint estimate. A practical starting point for defined-threshold assessments when the sample supports a clear, valid reaction.
Measures changes in turbidity generated by the LAL reaction. Kinetic or endpoint formats can support endotoxin quantification, with attention to sample turbidity, precipitation and reaction interference.
Uses substrate cleavage to generate a measurable color signal. Suitable assay formats can provide quantitative results, while sample color and effects on the enzymatic reaction require evaluation.
Detects endotoxin through activation of recombinant Factor C, commonly with a fluorescent readout. This approach avoids horseshoe-crab lysate, but still requires suitable sample conditions and controls.
Clarify the capture and detection configuration before selecting this route. Selective LPS capture followed by Factor C-based detection is different from an antibody-based LPS ELISA. A separation and washing step may reduce matrix carryover; performance depends on capture behavior and the selected detection system.
Measures cytokine responses from a suitable human monocyte-containing system. It can assess endotoxin and certain non-endotoxin pyrogens, depending on the system, sample compatibility and validation.
Historically assesses fever responses in rabbits. RPT is no longer an official European Pharmacopoeia test. Requests involving an existing RPT procedure require review of the current requirements and relevant in vitro options before a project scope is proposed.
The methods below answer different analytical questions. Compare the required output and likely sample challenges before considering reagent sensitivity or throughput.
On smaller screens, scroll horizontally to view all comparison columns.
| Approach | What it measures | Typical output | Key selection consideration |
|---|---|---|---|
| LAL gel-clot | Clot formation in the lysate reaction | Threshold assessment or endpoint estimate | Visual interpretation, lysate sensitivity and valid dilution |
| LAL turbidimetric | Turbidity associated with the reaction | Quantitative endotoxin result | Sample scattering, precipitation and reaction interference |
| LAL chromogenic | Color generated by substrate cleavage | Quantitative endotoxin result | Sample absorbance and effects on substrate conversion |
| rFC | Endotoxin activation of recombinant Factor C | Quantitative endotoxin result | Fluorescence effects and product-specific suitability |
| Selective solid-phase testing | Captured material assessed by the chosen detection system | Depends on capture and detection configuration | Recovery through capture and washing; antibody recognition and Factor C activation are different measurements |
| MAT | Cellular cytokine response to pyrogenic substances | Response assessed against a defined test design | Cell-system responsiveness, cytotoxicity and cytokine-assay interference |
| RPT | Temperature response in rabbits | Outcome under a specified legacy procedure | Current regulatory status and suitability of in vitro alternatives |
| Your starting question | A useful route to discuss |
|---|---|
| Does my sample meet a defined endotoxin threshold? | Consider gel-clot limit testing when the required threshold can be supported at a suitable dilution. Quantitative methods can also support a limit assessment. |
| I need quantitative data across samples or process stages. | Discuss turbidimetric, chromogenic or rFC testing. Select the readout using the required range, sample properties and reporting objective. |
| I want to avoid horseshoe-crab lysate reagents. | Discuss rFC, including the relevant verification or validation work. Reagent origin alone does not establish sample suitability. |
| Direct testing is affected by a complex formulation. | Review preparation and dilution first. Selective solid-phase capture may be worth assessing, but is not an automatic solution to interference or endotoxin masking. |
| Non-endotoxin pyrogens are part of the risk question. | Discuss a suitable MAT strategy. Endotoxin-specific testing alone may not address the broader objective. |
| I have an existing method or want to change methods. | Provide the current procedure and previous suitability data. Agree on the purpose of comparison, sample coverage and acceptance criteria before testing. |
Share the sample identity, concentration, formulation, available quantity and intended use, together with the target specification and any previous results. For devices, describe the material and any existing extraction procedure. For a method transfer, include the current protocol and reporting requirements.
Regulatory suitability depends on the product, intended use and applicable requirements. Fixed sensitivity, turnaround and documentation packages are not assumed from the method name; they are discussed as part of project planning.
No. The useful method depends on the testing objective, matrix, specification and required output. A technique that works for a simple aqueous sample may need different preparation or may be unsuitable for a complex formulation.
Gel-clot can be useful for a defined-threshold decision. If you need more detailed concentration data or comparisons across process stages, discuss a quantitative method. The target limit and achievable sample dilution remain important for either route.
No. Recombinant reagents are addressed in USP General Chapter <86>, and FDA guidance discusses their use. Product-specific suitability and applicable method requirements still need to be addressed; changing the reagent does not remove that responsibility.
No. MAT addresses a cellular pyrogen response, whereas endotoxin-specific assays answer a narrower question. The testing strategy should follow the product risk assessment and intended purpose rather than assuming either method can universally replace the other.
No. Antibody-based ELISA detects selected LPS epitopes. Selective capture followed by Factor C-based detection assesses captured endotoxin through a different mechanism. Confirm the analytical configuration and calibration before ordering or comparing results.
No. Dilution may reduce interference, but endotoxin assays must retain the ability to assess the required limit. If suitable conditions cannot be established within the relevant dilution constraints, additional preparation or another approach may be needed.
No. MS provides structural analytical information, while proficiency-related work evaluates aspects of method or laboratory performance. Neither should be treated as another name for a product endotoxin or pyrogen test.
RPT remains relevant to some historical procedures and method-transition discussions, but is no longer an official Ph. Eur. test. Its listing does not establish that it is required or appropriate for a new project. Current requirements and in vitro options should be reviewed first.
Send us your sample matrix, target specification and intended use. Our team will help define a testing scope and the information needed to move the project forward.
Explore All Endotoxin Testing Services →
References
